Literature DB >> 29345201

Clinical validation of nuclear factor kappa B expression in invasive breast cancer.

Anil Kumar Agrawal1, Ewa Pielka2, Artur Lipinski3, Michal Jelen3, Wojciech Kielan1, Siddarth Agrawal2.   

Abstract

Breast cancer is the most commonly diagnosed cancer in Polish women. The expression of transcription nuclear factor kappa B, a key inducer of inflammatory response promoting carcinogenesis and cancer progression in breast cancer, is not well-established. We assessed the nuclear factor kappa B expression in a total of 119 invasive breast carcinomas and 25 healthy control samples and correlated this expression pattern with several clinical and pathologic parameters including histologic type and grade, tumor size, lymph node status, estrogen receptor status, and progesterone receptor status. The data used for the analysis were derived from medical records. An immunohistochemical analysis of nuclear factor kappa B, estrogen receptor, and progesterone receptor was carried out and evaluation of stainings was performed. The expression of nuclear factor kappa B was significantly higher than that in the corresponding healthy control samples. No statistical difference was demonstrated in nuclear factor kappa B expression in relation to age, menopausal status, lymph node status, tumor size and location, grade and histologic type of tumor, and hormonal status (estrogen receptor and progesterone receptor). Nuclear factor kappa B is significantly overexpressed in invasive breast cancer tissues. Although nuclear factor kappa B status does not correlate with clinicopathological findings, it might provide important additional information on prognosis and become a promising object for targeted therapy.

Entities:  

Keywords:  Breast cancer; biomarker; immunohistochemistry; nuclear factor kappa B; transcription nuclear factor kappa B

Mesh:

Substances:

Year:  2018        PMID: 29345201     DOI: 10.1177/1010428317750929

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

Review 1.  Oral Microbiota Variation: A Risk Factor for Development and Poor Prognosis of Esophageal Cancer.

Authors:  Xiaobo Song; Ole K Greiner-Tollersrud; Huimin Zhou
Journal:  Dig Dis Sci       Date:  2021-09-09       Impact factor: 3.487

2.  The relationship between NFKB, HER2, ER expression and anthracycline -based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia.

Authors:  Christian Manginstar; Andi Asadul Islam; Daniel Sampepajung; William Hamdani; Agussalim Bukhari; Salman Ardy Syamsu; Nilam Smaradania; Muhammad Faruk
Journal:  Ann Med Surg (Lond)       Date:  2021-02-10

3.  Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis.

Authors:  Kaka Renaldi; Marcellus Simadibrata; Nur Rahadiani; Diah Rini Handjari; Andy William; Fira Sinuraya; Dadang Makmun
Journal:  Turk J Gastroenterol       Date:  2021-11       Impact factor: 1.852

Review 4.  Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.

Authors:  Khadijeh Barzaman; Rana Vafaei; Mitra Samadi; Mohammad Hossein Kazemi; Aysooda Hosseinzadeh; Parnaz Merikhian; Shima Moradi-Kalbolandi; Mohammad Reza Eisavand; Houra Dinvari; Leila Farahmand
Journal:  Cancer Cell Int       Date:  2022-08-19       Impact factor: 6.429

Review 5.  Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.

Authors:  Emily Smart; Svetlana E Semina; Jonna Frasor
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

6.  Pseudopterosin Inhibits Proliferation and 3D Invasion in Triple-Negative Breast Cancer by Agonizing Glucocorticoid Receptor Alpha.

Authors:  Julia Sperlich; Nicole Teusch
Journal:  Molecules       Date:  2018-08-10       Impact factor: 4.411

7.  Azaphilones from the Red Sea Fungus Aspergillus falconensis.

Authors:  Dina H El-Kashef; Fadia S Youssef; Rudolf Hartmann; Tim-Oliver Knedel; Christoph Janiak; Wenhan Lin; Irene Reimche; Nicole Teusch; Zhen Liu; Peter Proksch
Journal:  Mar Drugs       Date:  2020-04-10       Impact factor: 5.118

8.  ARID1A/BAF250a is significantly overexpressed in primary invasive breast cancer.

Authors:  Łukasz Szpon; Anil Agrawal; Michal Jelen; Artur Lipinski; Jerzy Rudnicki; Sebastian Makuch; Marta Woźniak; Mateusz Szmit; Siddarth Agrawal
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.